<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01620554</url>
  </required_header>
  <id_info>
    <org_study_id>P09-16 / BF2.649</org_study_id>
    <secondary_id>2010-019413-25</secondary_id>
    <nct_id>NCT01620554</nct_id>
  </id_info>
  <brief_title>Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA)</brief_title>
  <official_title>Minimum Effective Dose-Finding Study of BF2.649, in Patients With Moderate to Severe OSA, Experiencing EDS Despite Regular Use of nCPAP, and Patients Having Refused This Therapy - Randomized, Double Blind Study With BF2.649 or Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioprojet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bioprojet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter, double-blind, phase II, randomized, dose-response study in 5&#xD;
      parallel groups (dose-range).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obstructive sleep apnea (OSA) is a relatively common condition and is estimated to affect 2&#xD;
      to 4% of middle-aged adults&#xD;
&#xD;
      The study medication BF2.649 tested here is a novel, highly potent, selective, orally active&#xD;
      inverse agonist at the histamine H3 receptor, therefore strengthens histaminergic&#xD;
      transmission in the brain and increases wakefulness EDS is characterized by daytime&#xD;
      somnolence and sudden sleep episodes. This problem has several consequences, e.g., an&#xD;
      impairment of quality of life, an interference with activities of daily living and other&#xD;
      handicaps in the management of social and family affairs.&#xD;
&#xD;
      The primary endpoint of this study will be measured by the change in the well-validated&#xD;
      Epworth sleepiness scale (ESS). The ESS is a simple self-administered 8-item questionnaire.&#xD;
      The outcome is to get an impression about the level of the daytime sleepiness in several&#xD;
      real-life situations.&#xD;
&#xD;
      In this study, each patient will be treated during 2 weeks, and randomly assigned to one the&#xD;
      5 arms (BF2.649 at one of the 4 possible dosages or placebo).&#xD;
&#xD;
      The patient will then attend a end-of-treatment visit, in order to assess the particularly&#xD;
      the ESS score.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Epworth Sleepiness Scale scores (ESS)</measure>
    <time_frame>change of ESS at 2 weeks</time_frame>
    <description>ESS value compared from baseline (Day 0) and End of treatment period (Day 14)</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Obstructive Sleep Apnoea</condition>
  <condition>Excessive Daytime Sleepiness</condition>
  <arm_group>
    <arm_group_label>BF2.649 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BF2.649 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BF2.649 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BF2.649 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BF2.649</intervention_name>
    <description>1 capsule per week during 2 weeks</description>
    <arm_group_label>BF2.649 5mg</arm_group_label>
    <other_name>Pitolisant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BF2.649</intervention_name>
    <description>1 capsule per week during 2 weeks</description>
    <arm_group_label>BF2.649 10mg</arm_group_label>
    <other_name>Pitolisant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BF2.649</intervention_name>
    <description>1 capsule per week during 2 weeks</description>
    <arm_group_label>BF2.649 20mg</arm_group_label>
    <other_name>Pitolisant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BF2.649</intervention_name>
    <description>1 capsule per week during 2 weeks</description>
    <arm_group_label>BF2.649 40mg</arm_group_label>
    <other_name>Pitolisant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 capsule per week during 2 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion Criteria:&#xD;
&#xD;
          -  Patient with OSA (treated or not with nCPAP) and still complaining of EDS&#xD;
&#xD;
          -  Epworth Sleepiness Scale score &gt; or = to 11&#xD;
&#xD;
        Main exclusion Criteria:&#xD;
&#xD;
          -  Patient suffering from chronic severe insomnia in accordance with the International&#xD;
             Classification of Sleep Disorders, but without OSA&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evelyne De Paillette, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bioprojet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>June 8, 2012</study_first_submitted>
  <study_first_submitted_qc>June 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2012</study_first_posted>
  <last_update_submitted>June 13, 2012</last_update_submitted>
  <last_update_submitted_qc>June 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sleep disorder</keyword>
  <keyword>Obstructive Sleep Apnoea</keyword>
  <keyword>Excessive Daytime Sleepiness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Disorders of Excessive Somnolence</mesh_term>
    <mesh_term>Sleepiness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

